MedTrace Logo

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

NCT05177666 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-01-04

No results posted yet for this study

Summary

This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.

Conditions

  • Feasibility
  • Effectiveness
  • Safety
  • Targeted Molecular Therapy

Interventions

DRUG

Targeted therapy

Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.

Sponsors & Collaborators

  • Tianjin Happy Life Technology Co., Ltd.

    collaborator INDUSTRY

  • The University of Hong Kong-Shenzhen Hospital

    lead OTHER

Principal Investigators

  • Yongmei Li, MD · The University of Hong Kong-Shenzhen Hospital

  • Weitang Wu · The University of Hong Kong-Shenzhen Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2023-12-30
Completion
2024-03-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177666 on ClinicalTrials.gov